Horizontal transmission of the Leningrad–Zagreb mumps vaccine strain: A report of six symptomatic cases of parotitis and one case of meningitis

Atrasheuskaya, A. V.; Kulak, Mikhail V.; Fisenko, Elena G.; Karpov, Igor; Ignatyev, G. M.; Atrasheuskaya, Alena

doi:10.1016/j.vaccine.2012.06.055

Cited by 8 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite a better antibody response to L-Zagreb, the vaccination with this strain had some side effects and complications. There were cases of post-vaccination encephalitis caused by the L-Zagreb strain, and some cases of horizontal transmission of the vaccine virus were reported (3,4). The Rubini strain was officially not recommended by scientific authorities due to a weakened antibody response in comparison with the other vaccine strains, and its effectiveness of 33% was deemed to be inadequate (5).…”

Section: Introductionmentioning

confidence: 99%

Mumps in the Eastern Bohemia Region of the Czech Republic - a Serological Survey 2008-2012

Fajfr¹,

Štěpánová²,

Fajfrová³

2017

Cent Eur J Public Health

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Mumps in the Eastern Bohemia Region of the Czech Republic - a Serological Survey 2008-2012

Fajfr¹,

Štěpánová²,

Fajfrová³

2017

Cent Eur J Public Health

View full text Add to dashboard Cite

show abstract

“…Different mumps vaccines have shown rarely such transmission. [1][2][3][4][5] A study in US reported evidence of the transmission of rubella vaccine virus from vaccinees to two susceptible contacts. 6 With live varicella vaccines, there are at least three reports.…”

mentioning

confidence: 99%

Horizontal transmission of live vaccines

Kulkarni

Jadhav

Dhere

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Current view on novel vaccine technologies to combat human infectious diseases

Matić

Šantak

2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and production. Additionally, despite the enormous efforts to develop vaccines against some infectious diseases, the traditional technologies have not been successful in achieving this. At the same time, the concerns about emerging and re-emerging diseases urge the need to develop technologies that can be rapidly applied to combat the new challenges. Within the last two decades, the research of vaccine technologies has taken several directions to achieve safe, efficient, and economic platforms or technologies for novel vaccines. This review will give a brief overview of the current state of the novel vaccine technologies, new vaccine candidates in clinical trial phases 1-3 (listed by European Medicines Agency (EMA) and Food and Drug Administration (FDA)), and vaccines based on the novel technologies which have already been commercially available (approved by EMA and FDA) with the special reference to pandemic COVID-19 vaccines. Key points• Vaccines of the new generation follow the minimalist strategy.• Some infectious diseases remain a challenge for the vaccine development.• The number of new vaccine candidates in the late phase clinical trials remains low.

show abstract

Horizontal transmission of the Leningrad–Zagreb mumps vaccine strain: A report of six symptomatic cases of parotitis and one case of meningitis

Cited by 8 publications

References 10 publications

Mumps in the Eastern Bohemia Region of the Czech Republic - a Serological Survey 2008-2012

Mumps in the Eastern Bohemia Region of the Czech Republic - a Serological Survey 2008-2012

Horizontal transmission of live vaccines

Current view on novel vaccine technologies to combat human infectious diseases

Contact Info

Product

Resources

About